We're proud to see H.C. Wainwright Senior Biotech Analyst Mitchell Kapoor featured on Biotech TV this week, joining Brad Loncar to break down key data from EHA 2026.
H.C. Wainwright & Co.
4,927 posts
H.C. Wainwright & Co.
@HCWCO
H.C. Wainwright & Co. provides sector-focused Investment Banking, Equity Research, Sales & Trading, Strategic Advisory and Corporate Access services.
- H.C. Wainwright was proud to host over 70 biotech companies at this year's BioConnect Investor Conference at NASDAQ World Headquarters in New York City. The event brought together some of the most compelling voices across the biotech sector for a day of meaningful dialogue and
- 📅 Date Update: HCW's 4th Annual Cell Therapy Virtual Conference has moved to June 30–July 1, 2026! We've updated our conference dates to bring you an even better experience. Mark your calendars and join us for two days of cutting-edge insights. Cell therapy is advancing at an
- Join us for tomorrow's HCW@Home with @GossamerBio (GOSS)! Join CFO and COO, Bryan Giraudo, as he discusses the company's upcoming key FDA meeting in mid-June. The hour-long event will cover Gossamer's regulatory path forward for seralutinib in pulmonary arterial hypertension
00:00 - Join us for our upcoming KOL call with Dr. Howard Trachtman and Dr. Opeyemi Olabisi to discuss the evolving AMKD landscape in the wake of Maze's HORIZON Phase 2 data — and hear directly from H.C. Wainwright Senior Analyst Ananda Ghosh on why this is a must-attend conversation for
- Register now for our HCW@Home with @AltoNeuro (ANRO)! Join CEO, Amit Etkin, as he discusses Alto's approach to precision psychiatry, using brain activity measurements and other biological markers to match the right patients to the right treatments. The hour-long event will
00:00 - H.C. Wainwright & Co. is acting as financial advisor to @XOMARoyalty on @Ligand_LGND acquisition valued at $739M + contingent value. This post is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
- H.C. Wainwright & Co. is proud to announce our #1 ranking for the 44th consecutive quarter in PlacementTracker’s Market League Tables by transaction volume. In the first quarter of 2026, the firm completed approximately 90 transactions, reinforcing our position as the top firm in
- Mark your calendars. HCW's 2nd Annual Royalty Company Virtual Conference is set for May 6, 2026. Royalty companies are redefining how biopharma creates value, hear from the leaders doing it. Register today: hcwevents.com/royalty-compan…
- Register today for our upcoming Biotech Breakthroughs: A Monthly Discovery Series, where we focus on novel technologies, modalities, targets, and mechanisms approaching key value-generating clinical readouts with the potential to enable new treatments across multiple disease
- Register now for our HCW@Home with Shattuck Labs (STTK)! Join CEO Taylor Schreiber M.D./Ph.D., and CFO Andrew Neill as they discuss SL-325, the company's potentially first-in-class DR3 blocking antibody targeting inflammatory bowel disease (IBD). The hour-long event will cover
00:00 - H.C. Wainwright & Co acted as a Lead Manager on @Celldex Therapeutics' Follow-On Offering of $345M. This post is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
- Join us April 14–15, 2026 for H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference. Gain insights from companies shaping the future of inflammatory skin disease treatment and innovation. 🔗Register today at hcwevents.com/inflammatory-d…
